Recent Updates
Recently added Catalysts
CV Positive Sentiment

CapsoVision to Release Second Quarter 2026 Financial Results on August 13, 2026

Key Takeaway: CapsoVision, a medical technology company, will announce its second quarter 2026 financial results on August 13, 2026. Following the release, a conference call will be held to discuss the results and provide a corporate update. The company specializes in advanced imaging and AI-enabled capsule endoscopy solutions.

Market Sentiment Analysis

POSITIVE FACTORS

  • CapsoVision is advancing innovative imaging technology.
  • The upcoming financial results and conference call indicate transparency.
  • The company's focus on AI-enabled solutions shows commitment to improving diagnostics.

Full Press Release Details

SARATOGA, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the Company will release second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 9178774. The live and archived webcast of the conference call can be found on the Events page in the Investor Relations section of CapsoVision’s website.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.

Investor Relations Contact Leigh Salvo New Street Investor Relations Investors@CapsoVision.com

Frequently Asked Questions

When will CapsoVision release its Q2 2026 financial results?

CapsoVision will release its Q2 2026 financial results on August 13, 2026.

What time is the CapsoVision conference call?

The conference call will be held at 1:30 pm PT / 4:30 pm ET on August 13, 2026.

How can investors access the conference call?

Investors can access the conference call by dialing (800) 715-9871 or (646) 307-1963.

What is CapsoVision's flagship product?

CapsoVision's flagship product is the CapsoCam Plus®, a wire-free capsule endoscope.

Last updated: Jul 30, 2026